Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study

Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study is to report first preliminary results of patients enrolled in a phase II study that will investigate the activity and safety of docetaxel, oxaliplatin, and 5-fluorouracil (DOF) in combination with trastuzumab in human epidermal receptor-2 (HER-2) positive patients with advanced gastric or gastroesophageal junction (GEJ) cancer.Treatment consisted of docetaxel 70 mg/m combined with oxaliplatin 130 mg/m on day 1, and continuous infusion 5-fluorouracil mg/m days 1-5 plus trastuzumab at the standard dose on day 1, every 3 weeks for a maximum of 8 cycles.Fifteen patients were enrolled. The overall response rate was 60%. The median progression-free survival was 9.2 months (95% confidence interval [CI], 4.4-10.1 months) and the median overall survival was 19.4 months (95% CI, 8.9-21.1 months). Grade 3 neutropenia was observed in 3 patients (20%).The DOF plus trastuzumab seems active in HER-2 positive advanced gastric or GEJ cancer, final results of the phase II study are awaited.

Original languageEnglish
Pages (from-to)e10745
JournalMedicine
Volume97
Issue number20
DOIs
Publication statusPublished - May 2018

Keywords

  • Adenocarcinoma/drug therapy
  • Administration, Intravenous
  • Adult
  • Antineoplastic Agents/administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols
  • Disease-Free Survival
  • Docetaxel
  • Esophagogastric Junction/pathology
  • Female
  • Fluorouracil/administration & dosage
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Neoplasm Staging
  • Organoplatinum Compounds/administration & dosage
  • Oxaliplatin
  • Receptor, ErbB-2/antagonists & inhibitors
  • Stomach/pathology
  • Stomach Neoplasms/drug therapy
  • Taxoids/administration & dosage
  • Trastuzumab/administration & dosage

Fingerprint Dive into the research topics of 'Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study'. Together they form a unique fingerprint.

Cite this